National Heart, Lung, and Blood Institute; Notice of Closed Meeting, 30964 [2021-12142]
Download as PDF
<![CDATA[
30964
Federal Register / Vol. 86, No. 110 / Thursday, June 10, 2021 / Notices
Time: 10:00 a.m. to 5:00 p.m.
Agenda: To review and evaluate grant
applications.
Place: National Institutes of Health, 6705
Rockledge Drive, Bethesda, MD 20817
(Virtual Meeting).
Contact Person: Zhihong Shan, Ph.D., MD,
Scientific Review Officer, Office of Scientific
Review/DERA, National Heart, Lung, and
Blood Institute, National Institutes of Health,
6705 Rockledge Drive, Room 205–J,
Bethesda, MD 20892, (301) 827–7085,
zhihong.shan@nih.gov.
(Catalogue of Federal Domestic Assistance
Program Nos. 93.233, National Center for
Sleep Disorders Research; 93.837, Heart and
Vascular Diseases Research; 93.838, Lung
Diseases Research; 93.839, Blood Diseases
and Resources Research, National Institutes
of Health, HHS)
Dated: June 4, 2021.
David W. Freeman,
Program Analyst, Office of Federal Advisory
Committee Policy.
BILLING CODE 4140–01–P
National Institutes of Health
National Heart, Lung, and Blood
Institute; Notice of Closed Meeting
Pursuant to section 10(d) of the
Federal Advisory Committee Act, as
amended, notice is hereby given of the
following meeting.
The meeting will be closed to the
public in accordance with the
provisions set forth in sections
552b(c)(4) and 552b(c)(6), Title 5 U.S.C.,
as amended. The grant applications and
the discussions could disclose
confidential trade secrets or commercial
property such as patentable material,
and personal information concerning
individuals associated with the grant
applications, the disclosure of which
would constitute a clearly unwarranted
invasion of personal privacy.
khammond on DSKJM1Z7X2PROD with NOTICES
[FR Doc. 2021–12142 Filed 6–9–21; 8:45 am]
BILLING CODE 4140–01–P
DEPARTMENT OF HEALTH AND
HUMAN SERVICES
National Institutes of Health
Government-Owned Inventions;
Availability for Licensing
AGENCY:
National Institutes of Health,
HHS.
Notice.
The invention listed below is
owned by an agency of the U.S.
Government and is available for
licensing to achieve expeditious
commercialization of results of
federally-funded research and
development. Foreign patent
applications are filed on selected
inventions to extend market coverage
for companies and may also be available
for licensing.
FOR FURTHER INFORMATION CONTACT:
Benjamin Hurley; tel. 240–669–5092;
benjamin.hurley@nih.gov. Licensing
information may be obtained by
communicating with the Technology
Transfer and Intellectual Property
Office, National Institute of Allergy and
Infectious Diseases, 5601 Fishers Lane,
Rockville, MD 20852; tel. 301–496–
2644. A signed Confidential Disclosure
Agreement will be required to receive
copies of unpublished information
related to the invention.
SUPPLEMENTARY INFORMATION:
Technology description follows:
SUMMARY:
DEPARTMENT OF HEALTH AND
HUMAN SERVICES
Name of Committee: National Heart, Lung,
and Blood Institute Special Emphasis Panel;
Understanding and Reducing Cardiovascular
Disease in Type 1 Diabetes Mellitus.
Date: July 15, 2021.
Time: 11:00 a.m. to 5:00 p.m.
Agenda: To review and evaluate grant
applications.
Place: National Institutes of Health, 6705
Rockledge Drive, Bethesda, MD 20817
(Virtual Meeting).
Contact Person: Susan Wohler Sunnarborg,
Ph.D., Scientific Review Officer, Office of
Scientific Review/DERA, National Heart,
Lung, and Blood Institute, National Institutes
of Health, 6705 Rockledge Drive, Room 208–
Z, Bethesda, MD 20892, (301) 827–7987,
susan.sunnarborg@nih.gov.
(Catalogue of Federal Domestic Assistance
Program Nos. 93.233, National Center for
17:15 Jun 09, 2021
Dated: June 4, 2021.
David W. Freeman,
Program Analyst, Office of Federal Advisory
Committee Policy.
ACTION:
[FR Doc. 2021–12138 Filed 6–9–21; 8:45 am]
VerDate Sep<11>2014
Sleep Disorders Research; 93.837, Heart and
Vascular Diseases Research; 93.838, Lung
Diseases Research; 93.839, Blood Diseases
and Resources Research, National Institutes
of Health, HHS)
Jkt 253001
FRugally Optimized DNA Octamer
(FRODO): DNA Vector and Uses
Thereof for Detecting HIV and SIV
Description of Technology
Quantitative polymerase chain
reactions (qPCRs) are commonly
employed to enumerate genes of interest
among particular biological samples.
Insertion of PCR amplicons into plasmid
DNA is a mainstay for creation of
known quantities of target sequences to
standardize quantitative PCRs.
Typically, one amplicon is inserted into
one plasmid construct, the plasmid is
then amplified, purified, serially
diluted, and then quantified to be used
to enumerate target sequences in
PO 00000
Frm 00055
Fmt 4703
Sfmt 4703
unknown samples. As qPCR is often
used to detect multiple amplicons
simultaneously, individual qPCR
standards are often desired to be
normalized one to another. Unlike prior
methods using separate plasmid
constructs for each target sequence,
FRODO incorporates eight amplicons
into one plasmid construct ensuring
equivalent template copy numbers for
all amplicons. Amplifying, purifying,
diluting and quantifying one plasmid
construct rather than eight individual
constructs streamlines standard curve
qPCR analyses, reducing reagents and
simplifying normalization between
amplicons.
This technology is available for
licensing for commercial development
in accordance with 35 U.S.C. 209 and 37
CFR part 404, as well as for further
development and evaluation under a
research collaboration.
Potential Commercial Applications
• Clinical Detection, Monitoring of
Nucleic Acid Markers of HIV and
Immunological Health: FRODO may be
used to efficiently quantify target
sequences in unknown samples.
• FRODO is a single plasmid
containing 8 amplicons which can be
used to quantify several different strains
of SIV and HIV, cell number equivalents
for humans and nonhuman primates, T
cell receptor excision circles (humans
and nonhuman primates), and bacterial
16S and ampicillin resistance DNA.
• FRODO may offer improved, more
affordable, highly-sensitive nucleic
acid-based HIV quantification and/or
diagnostic response times, enhancing
patient treatment and interventions.
• FRODO can be used to quantify
levels of bacterial DNA in clinical
samples to determine potential sepsis.
• This technology is especially useful
in translational HIV research in which
human and nonhuman primate models
are used to study HIV pathogenesis,
informing public health responses.
Competitive Advantages
• A simplified workflow for qPCR
testing. Amplifying, purifying, diluting
and quantifying one plasmid construct
rather than multiple, individual
constructs streamlines standard curve
qPCR analyses, reducing reagents and
simplifying normalization between
amplicons.
• At present, there are a number of
antibody-based clinical tools that may
be used for diagnosing/detecting HIV,
but there are fewer products that
affordably detect/monitor nucleic acids
of HIV within cells, and immunological
health, and efficacy of medicaments
E:\FR\FM\10JNN1.SGM
10JNN1
]]>Agencies
[Federal Register Volume 86, Number 110 (Thursday, June 10, 2021)]
[Notices]
[Page 30964]
From the Federal Register Online via the Government Publishing Office [www.gpo.gov]
[FR Doc No: 2021-12142]
-----------------------------------------------------------------------
DEPARTMENT OF HEALTH AND HUMAN SERVICES
National Institutes of Health
National Heart, Lung, and Blood Institute; Notice of Closed
Meeting
Pursuant to section 10(d) of the Federal Advisory Committee Act, as
amended, notice is hereby given of the following meeting.
The meeting will be closed to the public in accordance with the
provisions set forth in sections 552b(c)(4) and 552b(c)(6), Title 5
U.S.C., as amended. The grant applications and the discussions could
disclose confidential trade secrets or commercial property such as
patentable material, and personal information concerning individuals
associated with the grant applications, the disclosure of which would
constitute a clearly unwarranted invasion of personal privacy.
Name of Committee: National Heart, Lung, and Blood Institute
Special Emphasis Panel; Understanding and Reducing Cardiovascular
Disease in Type 1 Diabetes Mellitus.
Date: July 15, 2021.
Time: 11:00 a.m. to 5:00 p.m.
Agenda: To review and evaluate grant applications.
Place: National Institutes of Health, 6705 Rockledge Drive,
Bethesda, MD 20817 (Virtual Meeting).
Contact Person: Susan Wohler Sunnarborg, Ph.D., Scientific
Review Officer, Office of Scientific Review/DERA, National Heart,
Lung, and Blood Institute, National Institutes of Health, 6705
Rockledge Drive, Room 208-Z, Bethesda, MD 20892, (301) 827-7987,
[email protected].
(Catalogue of Federal Domestic Assistance Program Nos. 93.233,
National Center for Sleep Disorders Research; 93.837, Heart and
Vascular Diseases Research; 93.838, Lung Diseases Research; 93.839,
Blood Diseases and Resources Research, National Institutes of
Health, HHS)
Dated: June 4, 2021.
David W. Freeman,
Program Analyst, Office of Federal Advisory Committee Policy.
[FR Doc. 2021-12142 Filed 6-9-21; 8:45 am]
BILLING CODE 4140-01-P
